Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: PaxMedica Inc. PXMD

PaxMedica Inc. (NASDAQ: PXMD) Announces Gold Sponsorship for The BRAIN Foundation’s Synchrony Symposia 2023

Posted on October 16, 2023 by MissionIR

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, recently announced its Gold Sponsorship of The BRAIN … Continue reading →

Posted in PaxMedica Inc. PXMD | Leave a comment

PaxMedica Inc. (NASDAQ: PXMD) CEO Presents ASD Pipeline and Corporate Presentation at H.C. Wainwright 25th Annual Global Investment Conference

Posted on October 12, 2023 by MissionIR

Howard Weisman, CEO of PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurological symptoms, recently participated in the H.C. … Continue reading →

Posted in PaxMedica Inc. PXMD | Leave a comment

MissionIRNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) to Serve as Gold Sponsor of Synchrony Symposia 2023

Posted on October 10, 2023 by MissionIR

PaxMedica (NASDAQ: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions, today announced its Gold Sponsorship of The BRAIN Foundation’s esteemed … Continue reading →

Posted in PaxMedica Inc. PXMD | Leave a comment

PaxMedica Inc. (NASDAQ: PXMD) Releases Compelling Video:  Progress Report on ASD and Hope for the Future

Posted on September 29, 2023 by MissionIR

In a powerful and informative video message, PaxMedica’s (NASDAQ: PXMD) Chairman and CEO, Howard Weisman, shares a progress report on the critical work being done to address the rising prevalence of Autism Spectrum Disorder (“ASD”) in the United States. This … Continue reading →

Posted in PaxMedica Inc. PXMD | Leave a comment

MissionIRNewsBreaks – Why PaxMedica Inc. (NASDAQ: PXMD) Is ‘One to Watch’

Posted on September 22, 2023 by MissionIR

PaxMedica (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. “The company’s lead programs are focused … Continue reading →

Posted in PaxMedica Inc. PXMD | Leave a comment

PaxMedica Inc. (NASDAQ: PXMD) Is ‘One to Watch’

Posted on September 13, 2023 by MissionIR

PaxMedica (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. The company’s lead programs are focused … Continue reading →

Posted in PaxMedica Inc. PXMD | Leave a comment